Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Brainstorm Cell Therapeutics Inc. is not very popular among insiders. Brainstorm Cell Therapeutics Inc. is a mediocre stock to choose.

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercia...

News

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

Ticker Report StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI - Get Free Report) in a report issued on Saturday. The brokerage set a "hold" rating on the biotechnology company's...\n more…

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

Zolmax StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI - Free Report) in a research report released on Friday morning. The firm issued a hold rating on the...\n more…

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Ticker Report Investment analysts at StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI - Get Free Report) in a report issued on Friday. The firm set a "hold" rating on the...\n more…

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated by Analysts at StockNews.com

Zolmax StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI - Free Report) in a research note issued to investors on Thursday. The firm issued a hold rating on the...\n more…

FY2024 Earnings Forecast for Brainstorm Cell Therapeutics Inc. Issued By Zacks Small Cap (NASDAQ:BCLI)

Ticker Report Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI - Free Report) - Analysts at Zacks Small Cap decreased their FY2024 earnings per share estimates for shares of Brainstorm Cell Therapeutics in a...\n more…

Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com

Ticker Report Equities researchers at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI - Get Free Report) in a research report issued to clients and investors on Thursday. The...\n more…